LANOVA AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: LM-108
Drug: An Anti-PD-1 Antibody

First Posted Date: 2022-01-20

Last Posted Date: 2024-10-11

Lead Sponsor: LaNova Australia Pty Limited

Target Recruit Count: 60

Registration Number: NCT05199753

Locations: 🇦🇺
ICON Cancer Centre, South Brisbane, Queensland, Australia
🇦🇺
Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia

and more 3 locations

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: LM-302
Drug: Toripalimab

First Posted Date: 2022-01-12

Last Posted Date: 2023-12-18

Lead Sponsor: LaNova Australia Pty Limited

Target Recruit Count: 20

Registration Number: NCT05188664

Locations: 🇦🇺
The Alfred, Melbourne, Australia

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy